Pragmatic paradigm for patient-reported outcome measure selection in lymphoma clinical trials: a rapid review study
The pragmatic paradigm presents a practical approach for selecting PROM(s) in lymphoma clinical trials. An appropriate PROM should conceptually align with the treatment goals and be acceptable to regulatory and HTA bodies. Thus, lymphoma clinical trials can generate more patient-focused data, contributing to improving patients' quality of life and advancing lymphoma care.
Authors
- Jennifer D Guo
- Abraham G. Hartzema (ORCID: https://orcid.org/0000-0002-3158-3400)
- Jonathon B. Cohen (ORCID: https://orcid.org/0000-0001-7696-2693)
- Adel Gehchan
- Nicole Tunstall
Institutions
- Emory University (US)
- Advanced Management Solutions (Greece) (GR)
- Québec International (CA)
- Winship Cancer Institute
- PDF Solutions (United States) (US)
Publication Details
- Journal
- BMJ Open
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1136/bmjopen-2025-106180
- Primary Topic
- Statistical Methods in Clinical Trials
- Type
- article
- Field-Weighted Citation Impact
- 0.00